𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of epirubicin in advanced malignant melanoma

✍ Scribed by Massimo Lopez; Carlo-Federico Perno; Paola Papaldo; Luigi Lauro; Fabrizio Ganzina; Aldo Barduagni

Publisher
Springer US
Year
1984
Tongue
English
Weight
194 KB
Volume
2
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Controlled study of DTICversusDTIC plus
Controlled study of DTICversusDTIC plus epirubicin in metastatic malignant melanoma
✍ Massimo Lopez; Carlo-Federico Perno; Luigi Lauro; Paola Papaldo; Fabrizio Ganzin πŸ“‚ Article πŸ“… 1984 πŸ› Springer US 🌐 English βš– 256 KB

Forty-two previously untreated patients with metastatic malignant melanoma were randomized to receive DTIC at a dose of 250 mg/m2/day 4 IV on days 1-5 or the same drug plus epirubicin (Epi-DX) at a dose of 90 mg/m2 on day 1. Cycles were repeated every 3 weeks. Partial responses were observed in two

Interferon in combination with vinblasti
Interferon in combination with vinblastine in advanced malignant melanoma. A phase I–II study
✍ Stein Gundersen; A. Flokkmann πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 288 KB πŸ‘ 2 views

Nineteen patients with advanced malignant melanoma were treated with a combination of recombinant alfa-interferon (a-IFN) and vinblastine (VBL). The a-IFN was administered subcutaneously daily at an initial dose of 3 X lo6 IU escalating to a maximal dose of 9 X lo6 U daily for the first 10 weeks fol